Omicron-specific Sinopharm COVID-19 vaccine candidates cleared for clinical trial - CNA

BEIJING: Two COVID-19 vaccine candidates developed by units of China National Biotec Group (CNBG) to target the Omicron variant were approved for clinical trials as boosters in Hong Kong, the Sinopharm subsidiary said on Saturday (Apr 16). Scientists world…

BEIJING: Two COVID-19 vaccine candidates developed by units of China National Biotec Group (CNBG) to target the Omicron variant were approved for clinical trials as boosters in Hong Kong, the Sinopha… [+1096 chars]

full article...